Amitriptyline (50mg)
Sarotena 50 mg Tablet is used for neuropathic pain, preventive treatment of migraine and depression. It is used in patients intolerant of or unresponsive to alternative treatment options for depression.
1 Strip of 10 Tablet
Image shown is a representation and may slightly vary from the actual product. Every effort is made to maintain accuracy of all information displayed.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Sarotena 50 mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Sarotena 50 mg Tablet is a tricyclic antidepressant. It works by increasing the levels of chemical messengers in the brain that help in regulating mood and treat depression. It also stops the movement of pain signals from nerves to the brain thereby relieving neuropathic pain (pain from damaged nerves).
Related Warnings
Sarotena 50 mg Tablet may cause excessive drowsiness and calmness with alcohol.
Sarotena 50 mg Tablet may be unsafe to use during pregnancy.
Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.
Sarotena 50 mg Tablet is probably unsafe to use during lactation. Limited human data suggest that the drug could represent a significant risk to the baby.
Do not drive unless you are feeling well.
Sarotena 50 mg Tablet may impair your alertness which may affect your ability to drive.
Sarotena 50 mg Tablet is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Sarotena 50 mg Tablet may not be needed in these patients. Please consult your doctor.
Sarotena 50 mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Sarotena 50 mg Tablet may be needed. Please consult your doctor.
Use of Sarotena 50 mg Tablet is not recommended in patients with severe liver disease.
